Stay updated on Elranatamab vs Lenalidomide Post-Transplant Clinical Trial
Sign up to get notified when there's something new on the Elranatamab vs Lenalidomide Post-Transplant Clinical Trial page.

Latest updates to the Elranatamab vs Lenalidomide Post-Transplant Clinical Trial page
- Check2 days agoChange DetectedThe page’s interface version or release revision indicator was updated from v3.5.2 to v3.5.3. This represents a system display/update rather than a change to the clinical trial details.SummaryDifference0.0%

- Check9 days agoChange DetectedMRD and PFS endpoints have been updated to IMWG 2025 terminology and subgroups, with added notes on next‑generation sequencing and longer follow-up. The study location count changed from 217 to 209 locations.SummaryDifference1%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedRemoved the disease keyword 'Multiple Myeloma' and the related topic 'MedlinePlus Genetics' from the page's topics section.SummaryDifference0.0%

- Check38 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0. This appears to be a minor update with no visible changes to study content or eligibility criteria.SummaryDifference0.0%

- Check45 days agoChange DetectedAdded related topics for Multiple myeloma and MedlinePlus Genetics; updated the page revision from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check59 days agoChange DetectedRemoved references to 'Multiple myeloma' and related topics (MedlinePlus Genetics) from the page. This reduces disease-specific context presented in the study record.SummaryDifference0.0%

Stay in the know with updates to Elranatamab vs Lenalidomide Post-Transplant Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Elranatamab vs Lenalidomide Post-Transplant Clinical Trial page.